Indivior

INDV

Market cap $4.2B

RICHMOND, Va. , Nov. 20, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq: INDV) today announced the Company has concluded the legacy U.S. Department of Justice (DOJ) matter by paying in full the outstanding obligation of $295 million associated with the matter.

RICHMOND, Va. , Nov. 19, 2025 /PRNewswire/ -- Indivior PLC (NASDAQ: INDV) today announced that it will participate in the Piper Sandler 37th Annual Healthcare Conference: Piper Sandler 37th Annual Healthcare Conference – New York City, NY Joe Ciaffoni, Chief Executive Officer, and Ryan Preblick, Chief Financial Officer, will host 1x1 / group meetings on Tuesday, December 2 nd.

INDV, PRLB, LVS and OII top Zacks' efficiency screen with strong margins and solid earnings surprises.

Medicaid and commercially insured patients with high adherence to SUBLOCADE® experienced lower relapse rates and reduced healthcare resource utilization Adherence to SUBLOCADE was associated with lower rates of infectious disease complications and improved chronic disease management in people with opioid use disorder (OUD) RICHMOND, Va. , Nov. 3, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq: INDV) presented three new scientific posters at the Academy of Managed Care Pharmacy (AMCP) Nexus 2025 conference last week, showcasing real-world evidence on the clinical and economic impact of monthly injectable buprenorphine in the treatment of OUD.

Indivior PLC ( INDV ) Q3 2025 Earnings Call October 30, 2025 8:00 AM EDT Company Participants Jason Thompson - Vice President of Investor Relations Joseph Ciaffoni - CEO & Director Patrick Barry - Chief Commercial Officer Ryan Preblick - Chief Financial Officer Conference Call Participants Yuchen Ding - Jefferies LLC, Research Division Chase Knickerbocker - Craig-Hallum Capital Group LLC, Research Division Christian Glennie - Stifel, Nicolaus & Company, Incorporated, Research Division Brandon Folkes - H.C. Wainwright & Co, LLC, Research Division Thibault Boutherin - Morgan Stanley, Research Division Presentation Operator Good day, and thank you for standing by.

Indivior is already profitable and cash-generative, and is set to grow significantly in 2026. Its key medication's delivery system offers opioid use disorder patients more reliable outcomes.

Indivior PLC (INDV) came out with quarterly earnings of $0.72 per share, beating the Zacks Consensus Estimate of $0.38 per share. This compares to earnings of $0.54 per share a year ago.

Q3'25 Total Net Revenue of $314m, up 2% YOY; Q3'25 SUBLOCADE® Net Revenue of $219m, up 15% YOY Announces the Optimization of Rest of World (ROW) Business Discontinued the Sales and Marketing Support of OPVEE® Expect Annual Operating Expense Savings of at Least $150m in 2026 On Track to Enter Phase II of the Indivior Action Agenda — Accelerate — January 1, 2026 Conference Call Scheduled for Today at 8:00 A.M. Eastern RICHMOND, Va.

RICHMOND, Va. , Oct. 28, 2025 /PRNewswire/ -- Indivior PLC (NASDAQ: INDV) today announced that it will participate in the Stifel 2025 Healthcare Conference: Stifel 2025 Healthcare Conference – New York City, NY Joe Ciaffoni, Chief Executive Officer, and Ryan Preblick, Chief Financial Officer, will host 1x1 / group meetings on Thursday, November 13 th.

RICHMOND, Va. , Oct. 16, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq: INDV) today announced that it will report its third quarter 2025 financial results on Thursday, October 30, 2025, at 7:00 a.m.